Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17056174 | 0.89 | PTGS2 (0.33) | RAPGEF4SMN1; SMN2GAAPOLBTRPV4 | |
| SCHEMBL8665535 | 0.87 | TRPV4 (0.32) | RAPGEF4SMN1; SMN2GAAPOLBTRPV4 | |
| SCHEMBL1094769 | 0.87 | TRPV4 (0.32) | RAPGEF4SMN1; SMN2GAAPOLBTRPV4 | |
| SCHEMBL16784556 | 0.83 | TRPV4 (0.38) | SMN1; SMN2TRPV4PTGS2TSHRPTGS1 | |
| SCHEMBL26512771 | 0.82 | CA1 (0.31) | TRPV4 | |
| SCHEMBL17203518 | 0.82 | POLB (0.37) | SMN1; SMN2POLBTRPV4TSHRL3MBTL1 | |
| SCHEMBL3906851 | 0.81 | RAPGEF4 (0.50) | RAPGEF4SMN1; SMN2GAAPOLBTRPV4 | |
| SCHEMBL16743708 | 0.79 | TRPV4 (0.50) | SMN1; SMN2GAAPOLBTRPV4PTGS2 | |
| SCHEMBL9339232 | 0.79 | RAPGEF4 (0.41) | RAPGEF4SMN1; SMN2GAAPOLBTRPV4 | |
| SCHEMBL1056557 | 0.78 | KDM4E (0.34) | SMN1; SMN2GAATRPV4ALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096558-B2 | N-sulfonylbenzamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| US-20130109696-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109696-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | RAPGEF4 3056/4885SMN1; SMN2 216/4885GAA 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.